ArticleNeurotrauma reports
Fibrin Degradation Products Regulate Endothelial Barrier Function in Traumatic Brain Injury via the Actin Cytoskeleton.
Article in Neurotrauma reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Traumatic brain injury (TBI)-associated coagulopathy (TBI-C) confers greater long-term disability and mortality rates compared to TBI without coagulopathy. Fibrin degradation products (FDPs) are generated during hyperfibrinolysis; however, the mechanism with which they contribute to endotheliopathy and blood-brain barrier (BBB) dysfunction in TBI-C remains unknown. Here, we performed comprehensive structural, functional and transcriptional analysis of human primary endothelial cells (ECs) treated with isolated human FDPs (D-dimer, Fragments D/E [FragD, FragE]) and a human primary co-culture consisting of ECs and astrocytes treated with plasma from patients with severe TBI with high FDP levels or healthy subjects. Exposure of ECs to FragD and FragE resulted in increased permeability of the EC barrier. While ECs treated with FragD and FragE maintained expression and membrane localization patterns of junctional proteins VE-Cadherin and ZO-1, super-resolution imaging showed a higher degree of intracellular localization of these proteins in vesicles. FragD and FragE exposure increased the formation of actin stress fibers and F/G-actin ratio. At the transcriptional level, FragD and FragE affected genes related to cell adhesion, cell migration and angiogenesis. A co-culture of ECs and astrocytes treated with human TBI plasma showed increased formation of actin stress fibers and F/G-actin ratio, and >300 differentially expressed genes, including genes governing cell-cell interactions and mechanotransduction. This study shows that FDPs mediate endothelial barrier dysfunction through disruption of the actin cytoskeleton and its interaction with junctional proteins. The positioning of FDPs at the molecular link between hyperfibrinolysis and endotheliopathy makes them therapeutic targets in TBI-C. Further work is needed to fully delineate the mechanistic framework of TBI-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.